Ryan Waddell, DO
Pulmonary Disease · Charleston, WVNPI 1528232683
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,637 of the $13,192 with a category attached, or 65.5%. 32 manufacturers reported payments, led by Intuitive Surgical at 33.9% of the total. Reporting peaked in 2023 at $5,794 and has fallen 82.7% since, to $1,003 in 2025. Among pulmonary disease clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $29.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Boehringer Ingelheim$734
- Novartis$732
- plus $4K from 26 others
What the payments were for
- Travel & lodging$1,33610%
- Food & beverage$8,63765%
- Education$3,21924%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $4,469 |
| GSK | 82 | $1,199 |
| AstraZeneca(2 entities) | 53 | $1,148 |
| Regeneron Healthcare Solutions, Inc. | 40 | $1,082 |
| Boehringer Ingelheim | 39 | $734 |
| Novartis | 40 | $732 |
| Actelion Pharmaceuticals US, Inc. | 17 | $686 |
| Sanofi | 22 | $535 |
| Genentech USA, Inc. | 21 | $316 |
| Pulmonx Corporation | 6 | $276 |
| Insmed, Inc. | 12 | $233 |
| Mylan Specialty L.p. | 12 | $197 |
| Verona Pharma, Inc. | 9 | $185 |
| Merck | 11 | $182 |
| Axsome Therapeutics, Inc. | 7 | $161 |
| Sunovion Pharmaceuticals Inc. | 11 | $149 |
| Johnson & Johnson(2 entities) | 3 | $145 |
| Jazz Pharmaceuticals Inc. | 7 | $117 |
| Pfizer | 6 | $97 |
| Mallinckrodt Hospital Products Inc. | 4 | $85 |
| Amgen | 5 | $83 |
| Electromed, Inc. | 10 | $80 |
| Advanced Respiratory, Inc | 4 | $60 |
| Vifor Pharma, Inc. | 2 | $52 |
| Eisai Inc. | 2 | $33 |
| Harmony Biosciences LLC | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Optinose US, Inc. | 1 | $25 |
| Galvanize Therapeutics, Inc | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Circassia Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$1,311
- FASENRA$267
- BREZTRI$267
- CHARTIS CATHETER$152
- ZEPHYR DELIVERY CATHETER$152
- ZEPHYR ENDOBRONCHIAL VALVE$152
- PULMONX CHARTIS TABLET CONSOLE$152
- UPTRAVI$142
- OPSUMIT$142
- AIRSUPRA$139
- MONARCH$110
- DUPIXENT$101
How this compares
$13,192 in reported general payments places this provider in the 90th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $381,204 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 231 | $214,984 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 148 | $144,875 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 15 | $140,176 |
| Dupixent PenDupilumab | 18 | $69,757 |
| Spiriva RespimatTiotropium Bromide | 97 | $61,963 |
| SymbicortBudesonide/Formoterol Fumarate | 119 | $45,759 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $42,732 |
| Incruse ElliptaUmeclidinium Bromide | 54 | $24,404 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $20,084 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $16,224 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 358 | $16,163 |
| Spiriva HandihalerTiotropium Bromide | 23 | $15,557 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 72 | $15,430 |
| EliquisApixaban | 13 | $7,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Tradjenta | $734 | $468,172158 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,199 | $298,344396 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,148 | $190,634267 claims |
| PfizerEliquis | $97 | $7,45713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Charleston
- Loay Al AsadiCharleston$13K
- Rayan IhleCharleston$4K
- Rajaninder SharmaCharleston$2K
- Mallinath KayiCharleston$2K
- David AdkinsCharleston$1K
- Vikhyath TerlaCharleston$747
- George ZaldivarCharleston$713
- Mark RadowCharleston$688
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.